With the help of world first-class technology platforms and skillful scientific teams in the field of antibody discovery and immunotherapy, Creative Biolabs now provides reliable and high-quality MHC/peptide complex production service for TCR-like antibody discovery.
1. Advantages of TCR-Like Antibody
TCR-like antibodies, or so-called TCRm antibodies, are antibodies that target disease-associated peptide–MHC-I complexes. They are similar to the TCR since they bind both the peptide and the MHC-I molecule and, therefore, their binding is both peptide-specific and MHC-restricted. Some advantages make TCR-like antibodies popular. First, they have higher affinity compared with TCR. Meanwhile, they have expanded the range of targetable antigens to include intracellular proteins without the delivery complications associated with intracellular antibodies. Moreover, they combine the intricate tumor specificity of TCRs with the biological properties of antibodies. This property makes them do not succumb to immune regulatory mechanisms that obstruct T-cell function in the tumor microenvironment. Due to their importance, TCR-like antibody is promising for cancer therapy. However, one of the main limitations in the production of TCR-like antibodies lies in the production of functional MHC/peptide complexes with high purity.
2. Production of MHC/Peptide Complex
The key for successful production of TCR-like antibody (using either conventional hybridoma or phage display technology) is having a purified recombinant MHC/peptide complex folded correctly in a native conformation that can be recognized by a T cell. After years of hard working and development, Creative Biolabs is proud to introduce our all-round protein expression systems to satisfy the production of MHC/peptide complexes for immunization and selection. We are capable of producing recombinant MHC/peptide complexes using bacterial system. Of note, they usually express in inclusion bodies in the cases. However, we are expert to refold them to generate correctly refolded monomers of high purity, in quantities that are sufficient for downstream applications. Furthermore, services are available to verify the correct refolding by structural and functional experiments. In addition, the monomers will be biotinylated for specificity and affinity characterization, and for antibody isolation.
3. Highlight Features of Our Service
➢ Fast MHC-associated peptide screening
Our one-stop service can simply start with high-throughput MHC-associated peptide proteomics assay. This assay helps you directly identify the peptides which are presented by antigen-presenting cells to T cells in just 3-4 weeks. Sequencing mass spectrometry will be used to get the final sequence.
➢ Versatile expression systems
We have a superior expression platform. E.coli system is the most widely used expression system for MHC/peptide complex production. However, we can also provide eukaryotic systems (yeast cells, insect cells, mammalian cells) upon request.
➢ Flexible antigen labeling
Site-specific labeling (biotin, fluorescent tags, etc) is also on our service list.
➢ Experienced scientific team
Professional experiment design and operation is promised for each specific case. Besides, we are good at timely troubleshooting.
Creative Biolabs is famous and professional in immunotherapy. We have built up good relationship with worldwide customers from either academic institution or pharmaceutical area. Our customized service is designed to meet your special needs if you have any requirements. Please feel free to contact us by e-mail for more details and we will get back to you as soon as possible.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE